Using PRP and Cord Blood in Treatment of Covid -19

July 24, 2020 updated by: Aljazeera Hospital

the Effect of PRP and Cord Blood in Improving the Symptoms of Covid-19

covid - 19 is a critical viral infection that affects humans

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Covid -19 pandemic started was declared in 2020

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Egypt
      • Giza, Egypt
        • Recruiting
        • Aljazeera( Al Gazeera) hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients with positive covid -19 and has symptoms and isolated in the hospital

Exclusion Criteria:

  • patients with negative test for covid -19

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: patients receiving LGF
Combination product: stem cells
giving stem cells to patients with covid - 19
No Intervention: patients not receiving LGF nor PRP
Active Comparator: patients receiving Platelet rich plasma
Combination product: stem cells
giving stem cells to patients with covid - 19

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the number of patients with positive covid 19 who will improve after receiving stem cells
Time Frame: 2 weeks
patients with positive covid 19 who will improve after receiving stem cells
2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Aljazeera Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 25, 2020

Primary Completion (Anticipated)

August 25, 2020

Study Completion (Anticipated)

September 1, 2020

Study Registration Dates

First Submitted

May 15, 2020

First Submitted That Met QC Criteria

May 15, 2020

First Posted (Actual)

May 19, 2020

Study Record Updates

Last Update Posted (Actual)

July 27, 2020

Last Update Submitted That Met QC Criteria

July 24, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • covid -19

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Virus

Clinical Trials on stem cells

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe